MMR vaccine license questioned after last FDA FOIA exposure by ICAN

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "AUSTIN, Texas, May 2, 2019 / PRNewswire / – & nbsp; In another important legal victory for the non-profit Informed Consent Action Network (ICAN) non-profit network, a new disclosure of the Federal Food and Drug Administration's Freedom of Information Act (FDA) revealed that the MMR vaccine has has been approved on the basis of clinical trials comprising in total less than 1,000 participants and many more adverse effects than previously recognized ones. "data-reactid =" 11 ">AUSTIN, Texas, May 2, 2019 / PRNewswire / – Another significant legal success in the non-profit Informational Consent Action Network (ICAN) non-profit action network, a new disclosure of the Freedom of Information Act of the Federal Food and Drug Administration ( FDA) revealed that the MMR vaccine was registered on the basis of clinical trials with fewer than 1,000 participants and many more adverse events than previously thought.

More

<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "" It is alarming that a call has been necessary to obtain this information, but it is more alarming to note that each time ICAN succeeds in obtaining a FOIA disclosure from the FDA, CDC or HHS, we discover another serious deficiency in their duty to ensure the health and health care of Americans, "said Del Bigtree, Founder of ICAN and host of the weekly medical news program "The HighWire". "Data-reactid =" 23 ">" It is alarming that an appeal is needed to obtain this information, but it is even more alarming than every time the ICAN wins by getting a FOIA disclosure to the FDA , CDC or HHS, we discover another serious deficiency in their duty to ensure the health and health care of Americans, "said Del Bigtree, Founder of ICAN and host of the weekly medical news program "The HighWire".

The MMR vaccine is at the heart of the vaccine debate. Here are some of the key facts from FDA-generated clinical trial reports, which the agency supported in authorizing the MMR:

• In total, eight clinical trials were conducted on fewer than 1,000 people. Only 342 children received the MMR vaccine.
• The safety review period followed only the "adverse events" for 42 days after the injection.
• More than half or a significant percentage of all participants in each of the eight trials developed gastrointestinal symptoms and upper respiratory tract infections
• All adverse events have been generically described as "other viruses" and are not considered in the safety profile of the license to practice.
• The control group received other vaccines against rubella or measles and rubella and none of the controls received placebo (inert substance such as an saline injection).

Bigtree, award-winning producer at an Emmy Award, and director of the documentary "Vaxxed: From Cover to Catastrophe", explains that the reason for the increased hesitation with regard to vaccines is not a unreasonable fear, but a growing awareness of corruption, secrecy and propaganda manifest vaccines and the pharmaceutical industry.

"Thanks to laws in this country that allow at least access to various government documents, we now know that the MMR vaccine has been licensed by an extremely small and limited group of children," said Bigtree. .

"But what's even more alarming is learning about known and recognized serious adverse events, but ignored to allow the MMR vaccine," adds Bigtree, noting that "it was after the track adverse events for only 42 days – imagine what they might have discovered had they monitored safety for three years compared to proper control, as they do for drugs. "

<p class = "canvas-atom web-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "View original content to download multimedia:http://www.prnewswire.com/news-releases/mmr-vaccine-licensing-called-into-question-following-icans-latest-foia-exposure-of-fda-coverup-300842503.html"data-reactid =" 46 "> View the original content for multimedia download: http: //www.prnewswire.com/news-releases/mmr-vaccine-licensing-called-en-question-suivant-icans-latest-foia – exhibition-of-fda-coverup-300842503.html